Slide Library

Review the latest information on NTM in clinical scenarios created by Drs. James F. Donohue, Kevin Winthrop, and Patrick A. Flume.

Review the latest information on IPF in clinical scenarios presented by Drs. Kevin R. Flaherty, David J. Lederer, and Fernando J. Martinez at a recent meeting in Washington, DC.

Review the latest information on the use of ICS in patients with COPD in these clinical scenarios as presented by Drs. Gary T. Ferguson, James F. Donohue, and Nicola A. Hanania at a recent meeting in Washington, DC.

Joel E. Fishman, MD, PhD discusses how to diagnose IPF with an interdisciplinary team. Can you report HRCT findings for suspected IPF using ERS/ATS descriptors?

IPF Diagnosis and Treatment with Case Review
Current diagnosis and individualized patient care are the foci of this case-based presentation. Derived from the PILOT Regional Symposium, this deck offers the participants interactive HRCTs, the evidence to make informed treatment decisions, and interesting clinical scenarios.

What’s on the Horizon: Potential Therapies in Clinical Trials
This deck is an excellent overview of Phase II, III, and IV clinical studies of emerging treatments for patients with IPF. Several early compounds are featured, organized by mechanism of action.

This resource from the Pulmonary Fibrosis Foundation provides an overview of IPF. It is designed as an introduction to the disease for patients and caregivers, and also provides a framework for patient/provider discussions about IPF diagnosis and management.

Experts emphasize the need for improved awareness of less common pulmonary diseases, so that clinicians not specializing in the area are alert to the possibility of these diagnoses and can initiate investigation, and facilitate early action. Explore real-world case-based scenarios in this slide presentation.

Non-small Cell Lung Cancer
Biomarker-driven targeted therapy of patients with NSCLC requires accurate diagnosis and staging. The pulmonary care team must acquire adequate biopsy tissue to enable histology, immunofluorescence and molecular biomarker testing.

Faculty: Momen M. Wahidi, MD, FCCP and W. Dean Wallace, MD

Care of patients with IPF has been transformed since the 2014 FDA approval of pirfenidone and nintedanib for the treatment of patients with IPF. Providers considering these treatments for their patients face decisions of which protocol is best for an individual patient, when to start, switch or combine treatments, and how to manage side effects and dosing. Explore real-world issues of treating patients with IPF. Presented in Los Angeles, California - October 2016.

Faculty: Paul W. Noble, MD and Jonathan Goldin, PhD, MD

Patient Session: Understanding Pulmonary Fibrosis
This resource from the Pulmonary Fibrosis Foundation provides an overview of IPF. It is designed as an introduction to the disease for patients and caregivers, and also provides a framework for patient/provider discussions about IPF diagnosis and management.

Faculty: David Lederer, MD, MS

This case-based presentation used for the PILOT Grand Rounds addresses current issues in IPF. Beginning with differential diagnosis, it introduces pharmacologic and non-pharmacologic management in the context of the 2011 and 2015 ATS/ERS guidelines. A summary of common comorbidities of IPF and an IPF Management Checklist are offered for managing multiple aspects of patient health.

Faculty:
Steven D. Nathan, MD; Kevin R. Flaherty, MD; David Lederer, MD, MS

This presentation addresses the following learning objectives:

• Identify presenting signs and symptoms that may indicate the presence of PH in patients with IIP
• Explain key test results that can help confirm PH diagnosis in patients with IIP
• Review data from studies evaluating treatments in patients IIP's

Steven D. Nathan, MD; Rajan Saggar, MD; Athol U. Wells, MD
Prepared for “What's New in Pulmonary Hypertension (PH) Associated with Idiopathic Interstitial Pneumonias: New Hope May Be on the Horizon," May 17, 2015

This presentation addresses the following learning objectives:

• Describe the evidence using triple therapy of NAC to treat IPF
• Discuss the efficacy, safety, and clinical application of new treatment options for patients with IPF

Luca Richeldi, MD, PhD; Harold R. Collard, MD; Kevin K. Brown, MD; Marilyn K. Glassberg, MD
Prepared for “Translating IPF Clinical Trials to Real Life Patients:
A Case-Based Symposium," May 19, 2015

This presentation addresses the following learning objectives:

• Explain the considerations associated with clinical evaluation, imaging, and surgical biopsy in differentially diagnosing IPF
• Identify opportunities for interdisciplinary collaboration and consultation and key aspects of guideline recommendations that can facilitate early and accurate IPF diagnosis
• Summarize the current understanding of the IPF disease process and strategies that can help measure disease progression and treatment response
• Evaluate clinical trial data on available and emerging treatments for IPF
• Identify opportunities for referral as part of multidisciplinary IPF management plan

Prepared for 2014-2015 Grand Round Series.

This presentation addresses the following learning objectives:

• Explain the considerations associated with clinical evaluation, imaging, and biopsy, in terms of differentially diagnosing IPF
• Identify opportunities for interdisciplinary collaboration and consultation and key aspects of guideline recommendations that can facilitate early and accurate IPF diagnosis

David Lederer, MD, MS
Prepared for “A New Era in IPF” Regional Symposia 2014/15.

This presentation addresses the following learning objectives:

• Summarize the current understanding of the IPF disease process and strategies that can help measure disease progression and treatment response
• Identify approaches to IPF management that are covered in current guidelines, taking into account the strength of relevant recommendations
• Evaluate clinical trial data on available and emerging treatments for IPF

Steven Nathan, MD
Prepared for “A New Era in IPF” Regional Symposia 2014/15.

This presentation addresses the following learning objectives:

• Identify approaches to IPF management that are covered in current guidelines, taking into account the strength of relevant recommendations
• Formulate a plan, based on available data and expert consensus, for addressing acute exacerbations of IPF
• Explain the impact and treatment of common comorbidities of IPF

Steven D. Nathan, MD
Prepared for “A New Era in IPF” Regional Symposia 2014/15.

This presentation addresses the following learning objectives:

• Formulate a plan, based on available data and expert consensus, for addressing acute exacerbations of IPF
• Identify opportunities for referral as part of the multidisciplinary IPF management plan

Jeffrey James Swigris, DO, MS; A. Whitney W. Brown, MD
Prepared for “A New Era in IPF” Regional Symposia 2014/15.

Kevin R. Flaherty, MD, MS
University of Michigan Health System

Presented at: “Confronting the Challenges of Idiopathic Pulmonary Fibrosis Diagnosis and Management” symposium on May 21, 2013 at the ATS International Conference

Steven D. Nathan, MD
Inova Fairfax Hospital

Presented at: “Confronting the Challenges of Idiopathic Pulmonary Fibrosis Diagnosis and Management” symposium on May 21, 2013 at the ATS International Conference

David J. Lederer, MD, MS
Columbia University Medical Center

Presented at: “Confronting the Challenges of Idiopathic Pulmonary Fibrosis Diagnosis and Management” symposium on May 21, 2013 at the ATS International Conference

Gregory P. Cosgrove, MD
National Jewish Health

Presented as a webinar January 2013.

Kevin R. Flaherty, MD, MS
University of Michigan Health System

Presented as a webinar December 2012.